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Abstract: PURPOSE To compare 12-month treatment outcomes of eyes receiving aflibercept or ranibizumab
for macular oedema secondary to central retinal vein occlusion (CRVO) in routine clinical practice.
METHODS 296 treatment-naïve eyes receiving either aflibercept (171 eyes, 2 mg) or ranibizumab (125
eyes, 0.5 mg) for macular oedema secondary to CRVO were recruited retrospectively from centres us-
ing the prospectively designed FRB! registry. The primary outcome measure was the mean change in
LogMAR letter scores of visual acuity (VA). Secondary outcomes included change in central subfield
thickness (CST), injections and visits, time to first grading of inactivity, switching and non-completion
from baseline to 12 months. RESULTS Baseline VA (SD) was somewhat better in aflibercept- versus
ranibizumab-treated eyes (42.5 ± 25.5 letters versus 36.9 ± 26 letters; p = 0.07) with similar CST (614
(240) ฀m versus 616 (234) ฀m: p = 0.95). The 12-month adjusted mean (95%CI) VA change was +16.6
(12.9, 20.4) letters for aflibercept versus +9.8 (5.5, 14.1) letters for ranibizumab (p = 0.001). The mean
(95%CI) adjusted change in CST was significantly greater in aflibercept- versus ranibizumab-treated eyes:
-304 (-276, -333) µm versus -252 (-220, -282) µm (p < 0.001). Both groups had a median (Q1, Q3) of 7 (5,
9) injections and 10 (8,13) visits. Aflibercept-treated eyes became inactive sooner than ranibizumab (p =
0.02). Switching occurred more commonly from ranibizumab (26 eyes, 21%) than from aflibercept (9 eyes,
5%) (p < 0.001). CONCLUSION Both aflibercept and ranibizumab improved VA and reduced CST in
eyes with CRVO in routine clinical practice, with aflibercept showing significantly greater improvements
in this comparative analysis.
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ABSTRACT.
Purpose: To compare 12-month treatment outcomes of eyes receiving aflibercept or
ranibizumab for macular oedema secondary to central retinal vein occlusion (CRVO) in
routine clinical practice.
Methods: 296 treatment-na€ıve eyes receiving either aflibercept (171 eyes, 2 mg) or
ranibizumab (125 eyes, 0.5 mg) for macular oedema secondary to CRVO were recruited
retrospectively from centres using the prospectively designed FRB! registry. The primary
outcome measure was the mean change in LogMAR letter scores of visual acuity (VA).
Secondary outcomes included change in central subfield thickness (CST), injections and visits,
time to first grading of inactivity, switching and non-completion from baseline to 12 months.
Results: Baseline VA (SD) was somewhat better in aflibercept- versus ranibizumab-
treated eyes (42.5  25.5 letters versus 36.9  26 letters; p = 0.07) with similar CST
(614 (240) lm versus 616 (234) lm: p = 0.95). The 12-month adjusted mean (95%CI) VA
change was +16.6 (12.9, 20.4) letters for aflibercept versus +9.8 (5.5, 14.1) letters for
ranibizumab (p = 0.001). The mean (95%CI) adjusted change in CST was significantly
greater in aflibercept- versus ranibizumab-treated eyes: 304 (276, 333) µm versus
252 (220, 282) µm (p < 0.001). Both groups had a median (Q1, Q3) of 7 (5, 9)
injections and 10 (8,13) visits. Aflibercept-treated eyes became inactive sooner than
ranibizumab (p = 0.02). Switching occurred more commonly from ranibizumab (26 eyes,
21%) than from aflibercept (9 eyes, 5%) (p < 0.001).
Conclusion: Both aflibercept and ranibizumab improved VA and reduced CST in eyes
with CRVO in routine clinical practice, with aflibercept showing significantly greater
improvements in this comparative analysis.
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Introduction
Treatment of central retinal vein occlu-
sion (CRVO) has progressed from
prevention of sight-threatening seque-
lae (Hayreh 2003) to vascular endothe-
lial growth factor (VEGF) inhibitors,
which randomized controlled trials
(RCTs) suggest can improved vision
significantly (Campochiaro et al. 2011;
Boyer et al. 2012; Brown et al. 2013;
Korobelnik et al. 2014). There are,
however, limited data showing that
these impressive RCT outcomes are
being achieved in routine clinical care
and whether the licenced drugs, afliber-
cept and ranibizumab, are equivalent in
the general population.
Randomized controlled trials
(RCTs) mandate frequent intravitreal
injections that pose a significant treat-
ment burden which is difficult to
always achieve in routine clinical prac-
tice (Kiss et al. 2014; Lotery & Regnier
2015; Stallworth et al. 2020). Various
retrospective observational analyses
suggest that fewer injections are given
in the first 12 months than in RCTs,
with correspondingly lower visual acu-
ity gains (Chatziralli et al. 2017, 2018;
Kitagawa et al. 2018; Callizo et al.
2019). On average, 4–5 injections were
given in the first 12 months, resulting
in an average visual gain of approxi-
mately 1.2 lines (Lotery & Regnier
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2015; Gale et al. 2020; Stallworth et al.
2020).
The LEAVO study was a random-
ized clinical trial that reported that
ranibizumab was non-inferior to
aflibercept in CRVO (Hykin et al.
2019). There were selected cohorts
treated under controlled conditions
following a strict induction protocol
followed by a PRN regimen from week
16 to week 96, which may be similar to
routine clinical care. The VA outcomes
at 12 months were similar between
aflibercept- and ranibizumab-treated
eyes (Hykin et al. 2019). The SCORE2
study reported that bevacizumab was
‘non-inferior’ to aflibercept in a hetero-
geneous group of eyes with CRVO or
HRVO (Scott et al. 2017).
The quality of data from routine
clinical practice is variable. ‘Mining’
large data sets from electronic medical
records currently produces lower qual-
ity data, such as a recent report using
data from the US Retina database,
where baseline visual acuity could not
be identified in 130 25 of 301 06 (35%)
of eyes receiving anti-VEGF treatment
for age-related macular degeneration
(Kiss et al. 2020). Outcomes registries
with prespecified mandatory fields –
such as the Fight Retinal Blindness!
Project – require users to enter all data
within prespecified ranges for the visit to
be ‘finalized’ and accepted into the
database. Finalization rates consistently
exceed 95% of recorded visits. The
additional effort users make produces
higher quality, complete data sets.
Here, we report a comparative anal-
ysis of 12-month treatment outcomes
of a large cohort of patients in routine
clinical practice who received afliber-
cept or ranibizumab for macular
oedema secondary to CRVO from




We conducted a retrospective analysis
of eyes with CRVO treated with
approved intravitreal anti-VEGF
agents. Treatment was tracked in rou-
tine clinical practice within the prospec-
tively designed retinal vein occlusion
module of the Fight Retinal Blindness!
Registry (Gillies et al. 2014). Partici-
pants were treatment-na€ıve and man-
aged at clinics in Australia, France,
Switzerland and the United Kingdom.
Ethics and data protection approval
was obtained from the University of
Sydney and the Royal Australian and
New Zealand College of Ophthalmolo-
gists (HREC#16.09), the French Insti-
tutional Review Board (2017_CLER-
IRB_ll-05), the Cantonal Ethics Com-
mission in Zurich (PB_2016-00264) and
the Caldicott Guardian of the Royal
Free London NHS Foundation Trust
(Dr Kilian Hynes). The study adhered
to the STROBE checklists for reporting
observational studies (von Elm et al.
2008) and followed the tenets of the
Declaration of Helsinki. All patients
gave informed consent. An ‘opt-in’
informed consent was sought from
patients from France, Switzerland and
the United Kingdom. An ‘opt-out’
patient consent was approved by Ethics
committees in Australia.
Data sources and measurements
Data were collected at each clinical visit
including the number of letters read on
a logarithm of the minimum angle of
resolution (logMAR) VAChart (highest
of uncorrected, corrected or pinhole),
the activity (presence of intraretinal
cystoid changes) of cystoid macular
oedema (CME [yes/no]), the central
subfield thickness (CST [µm]) measured
using spectral-domain optical coherence
tomography (OCT), treatment given,
other ocular procedures and ocular
adverse events. Relevant systemic risk
factors or ocular conditions were
recorded at baseline only, as was the
type of RVO (CRVO, hemi-RVO or
branch-RVO) (McAllister et al. 2014),
and if a fluorescein angiogram was
performed, whether macular or periph-
eral ischaemia was documented. Drug
choice and treatment frequency were at
the physician’s discretion in consulta-
tion with the patient reflecting routine
clinical practice.
Patient selection
Treatment-na€ıve eyes that started treat-
ment with either ranibizumab (0.5 mg
Lucentis, Genentech Inc/Novartis) or
aflibercept (2 mg Eylea, Bayer) from 1
June 2014 to 1 June 2019 were studied.
Eyes with hemi-RVO or branch-RVO
were excluded. Eyes that had at least
three visits and were followed for
12 months were defined as ‘com-
pleters’. Switchers were defined as eyes
that received ≥2 injections of the other
drug prior to switching. Visits occur-
ring after the switch were not included
in this analysis. Eyes that did not
complete 12 months of observations
were defined as ‘non-completers’.
Outcomes
The main outcome was the mean
change in VA at 12 months between
anti-VEGF agents. Secondary out-
comes were the mean change in CST,
number of visits and the number of
injections. Other event-based outcomes
of interest were first grading of CME
inactivity, switching and non-
completion rates over 12 months.
Statistical analysis
Descriptive data were summarized using
the mean, standard deviation, median,
first and third quartiles, and percentages
where appropriate. Eyes were observed
from the first treatment visit to their 12-
month (365  30 days) visit. T-tests,
Wilcoxon signed-rank tests, chi-square
tests and Fisher’s exact tests were used
as appropriate to compare baseline
characteristics between ranibizumab-
and aflibercept-treated eyes. Calculation
of crude visual and anatomic outcomes
at 12 months used the last observation
carried forward (LOCF) for switchers
and non-completers. We used longitu-
dinal generalized additive mixed-effects
models to compare VA and CST out-
comes between the treatments over the
12-month period with the interaction
between injection group and time as the
main predictor. The longitudinal mod-
els included all visits up until 12 months
from completers, non-completers and
switchers without imputation of missing
data (i.e. LOCF). Visits occurring after
an eye switched drugs were not
included. We adjusted for age and
baseline VA or CST as fixed effects,
and nesting of outcomes within doctor
and patient (for bilateral cases) as
random effects. We used predictions
from these models to plot predicted
VA and CST, and the difference in the
mean predicted VA and CST, over
12 months for each drug.
Generalized Poisson linear mixed
models were used to compare visits
and injections with an offset for log
days of follow-up. Kaplan–Meier sur-
vival analysis was used to assess the
time to first grading of CMO inactivity,
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non-completion and switching. A Cox-
proportional hazards model was used
to compare time to inactivity between
treatment groups. Generalized Poisson
and Cox-proportional hazards models
were adjusted for age, baseline VA and
baseline CST as fixed effects, and
nesting of outcomes within doctor
and patient as random effects.
All analyses were conducted using R
version 4.0.0 (http://www.R-project.
org/) using the glmmTMB (V1.0.1)
package for generalized linear mixed-
effects regression, the mgcv (V1.8-31)
package for generalized additive mixed
models and the coxme (V2.2-16) and
survival (V3.1-12) packages for time-to-
event analyses (R Core Team 2020).
Results
Study participants
We identified 296 treatment-na€ıve
patient eyes (125 ranibizumab and 171
aflibercept) in 291 patients with cystoid
macular oedema secondary to CRVO
that started treatment with either rani-
bizumab or aflibercept from 1 June
2014 to 1 June 2019 (Table 1).
There were no statistically significant
differences at baseline in eyes grouped
by VEGF inhibitor. Eyes receiving
ranibizumab were slightly older (73
versus 71 years; p = 0.14), had lower
mean baseline visual acuity (36.9 versus
42.5 letters; p = 0.07), more presented
with VA ≤ 35 letters (45% versus 38%,
p = 0.29) and were less likely to have a
history of systemic hypertension and
glaucoma than those receiving afliber-
cept. The groups had very similar mean
(SD) baseline CST (ranibizumab 614
(240) lm versus aflibercept 616
(234) lm; p = 0.95). Fundus fluores-
cein angiography (FFA) was per-
formed in 60% of all eyes studied.
Twenty eyes overall that had docu-
mented macular ischaemia were more
likely to have baseline visual acuity ≤35
letters (p = 0.01); however, the treat-
ment groups had no significant differ-
ence in documented ischaemia at
baseline including both macular (7%)
and peripheral ischaemia (25%).
Visual outcomes at 12 months
Mean crude VA improvement (95%
confidence interval [CI]) was higher for
aflibercept than for ranibizumab (+13.1
letters [9.4, 16.8] versus +9.9 [5.8, 14.1]
(p = 0.26), including eyes that switched
or dropped out (using LOCF)
(Table 2).
This trend was more pronounced in
eyes presenting with baseline VA ≤ 35
letters (38% in the aflibercept-treated
group and 45% in the ranibizumab-
treated group) with mean crude VA
improvement in the aflibercept group
of +24.6 (18.5, 30.7) letters versus +16.6
(10.4, 22.8) letters in the ranibizumab
group (p = 0.07) from similar mean
baseline VA: 13.7 (13.7) letters versus
11.9 (13.2) letters (p = 0.46)
(Table S1). The treatment groups
started with very similar proportions
of eyes with VA ≥ 70 at baseline
(13%); however, more eyes in the
aflibercept group (42%) had VA ≥ 70
letters at 12 months than in the ranibi-
zumab group (30%; p = 0.05).
The generalized additive mixed
model (Methods) predicted a mean
adjusted VA change (95% CI) that
was greater with aflibercept +16.6
(12.9, 20.4) letters than +9.8 (5.5,
14.1) letters with ranibizumab group
(p = 0.001). The mean adjusted VA
over 12 months for each group is
shown in Fig. 1A, while Fig. 1B shows
the difference in longitudinal trend
between drugs. Eyes on aflibercept
achieved larger gains in VA than
ranibizumab which are statistically sig-
nificant from the first week onwards to
12 months.
Macular thickness
Both drugs were effective in reducing
macular thickness (Table 2). Mean
baseline CST (SD) was very similar
(ranibizumab 614 (240) lm versus
aflibercept 616 (234) lm; p = 0.95);
however, at 12 months, the mean
CST (SD) was significantly lower in
the aflibercept group at 313 (157) lm
versus 370 (180) lm in the ranibizu-
mab group (p = 0.01). The difference in
crude effect on CST of aflibercept
compared with ranibizumab was more
marked in the 121 eyes (41%) present-
ing with poor VA ≤ 35 letters
(Table S1). This subset presented with
similar mean CST of 716 (286) lm in
the aflibercept group versus 693
(256) lm in the ranibizumab group
(p = 0.67); however, the aflibercept-
treated eyes had lower final CST of
296 (145) lm versus 388 (218) lm
(p = 0.03) and greater crude CST
change of 419 (498, 341) lm ver-
sus 305 (389, 221) lm (p = 0.08),
than the ranibizumab-treated eyes at
12 months.
Application of a generalized additive
mixed model predicted a greater mean
adjusted CST change (95% CI) for
aflibercept of 304 (276, 333) lm
vs. 252 (220,282) for ranibizumab
(p < 0.001). The statistically significant
longitudinal trend favouring aflibercept
Table 1. Demographic characteristics of all treatment-na€ıve CRVO eyes commencing ranibizu-
mab or aflibercept treatment 2014–2019.
Overall Ranibizumab Aflibercept p-value
Eyes, n 296 125 171
Patients, n 291 122 170
Female, % 47% 47% 47% 1.00
Age, mean (SD) 72 (13) 73 (12) 71 (13) 0.14
VA, mean (SD) 40.1 (25.8) 36.9 (26) 42.5 (25.5) 0.07
≥70 letters, % 13% 13% 13% 1.00
≤35 letters, % 41% 45% 38% 0.29
FFA Performed, n (%)* 176 (59%) 75 (60%) 101 (59%) 0.96
Macular Ischaemia, n (%) 20 (7%) 9 (7%) 11 (6%) 0.81
Peripheral Ischaemia, n (%) 75 (25%) 37 (30%) 38 (22%) 0.16
CST, mean (SD) 615 (236) 614 (240) 616 (234) 0.96
Hypertension, % 60% 58% 61% 0.80
Glaucoma, % 16% 14% 17% 0.53
Country, %
Australia 29% 30% 29%
France 31% 39% 25%
Switzerland 24% 15% 32%
United Kingdom 15% 16% 15%
n = number, SD = standard deviation, VA = visual acuity (logMAR letters), FFA = fundus
fluorescein angiography, CST = central subfield thickness (in microns).
* Not mandatorily performed or documented.
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is shown in Fig. 1C,D extending from
the first 2 weeks through 12 months.
Treatments and visits
The completers (80%) in the aflibercept
group had a median (Q1, Q3) of 8 (5, 9)
injections, and 10 (8, 13) visits, while the
completers (79%) in the ranibizumab
group had 6 (4, 9) injections and 10 (7,
14) visits (p = 0.62, 0.84; Table 2). Thus,
aflibercept-treated eyes received some-
what more injections, but this difference
was not statistically significant. The
range in injections delivered was from
1 to 13 over 12 months. Both groups
received a similar number of injections:
completers had a mean total of 7.4
injections (7.5 aflibercept, 7.2 ranibizu-
mab) over 12 months. The mean num-
ber of injections in the first 6 months
was 4.8 (4.8 aflibercept, 4.7 ranibizu-
mab), and 2.6 (2.7 aflibercept, 2.6
ranibizumab) in the second 6 months.
The median time between each of the 1st
to 5th injections was 4, 4, 6 and 6 weeks.
Twenty-nine eyes received fewer than 4
injections, and in 12 of these, the final
was VA <20 letters; however, in the
other 17 eyes, the median final VA was
76 (55, 80) letters at 12 months. Catar-
act surgery was performed in 9
ranibizumab-treated eyes and 4 afliber-
cept eyes with YAG capsulotomy per-
formed in one eye from each group.
Inactivity, switching and loss to follow-up
Kaplan–Meier survival analysis was
used to compare ranibizumab and
aflibercept in terms of time to first
grading of inactivity, switching and loss
to follow-up (Fig. 2). Inactivity was
recorded at least once in 12 months in
227 eyes (96% of completers), with the
first occurrence at a median (Q1, Q3) of
58 (29, 98) days. The Cox-proportional
hazards model predicted aflibercept
achieved inactivity sooner than ranibi-
zumab (p = 0.02).
Thirty-five eyes (12%) switched
treatment within 12 months, more
commonly from ranibizumab (26 eyes,
21%) than from aflibercept (9 eyes,
5%) (p < 0.001) (Table 2). The median
(Q1, Q3) time to switching for all eyes
combined was 155 days (112, 252).
Eyes switched from ranibizumab to a
dexamethasone implant (6 eyes), to
aflibercept (17 eyes) or to bevacizumab
(2 eyes) with a median VA of 59 (36,
65) letters at the time of switch. Eyes
switched from aflibercept with a lower
median VA of 45 (29, 50) letters at the
time of switch to a dexamethasone
implant (5 eyes) or ranibizumab (4
eyes).
Sixty eyes (20%) dropped out before
12 months. The non-completion rate
was similar in the ranibizumab group
(21%) and the aflibercept group (20%).
The overall median (Q1, Q3) time to
dropout was 193 days (119, 271). Doc-
umented reasons for loss to follow-up
included 2 deaths, a medical con-
traindication in 1 patient, futility of
treatment in 3 eyes, 7 patients declined
further treatment while 10 patients
went to another doctor.
Adverse events
Macular changes affecting vision were
newly observed during follow-up in 28
eyes (ERM, macular hole, pigment
clumping, atrophy) with a mean (SD)
baseline VA of 15 (20) letters and mean
12-month VA of 22 (28) letters. Neo-
vascular complications in either the
anterior segment (16 eyes) or posterior
segment (17 eyes) led to poor outcomes
with a combined mean (SD) VA of 13
(21) letters at 12 months. Eighty-three
eyes received panretinal photocoagula-
tion with a 12-month mean VA (SD) of
36 (30) letters from a baseline VA of 26
(28.5) letters. Eyes receiving PRP (83
eyes) had fewer injections (SD) with 6.4
(3.4) compared to 7.3 (3) in eyes that
did not receive PRP (p = 0.04). Vitre-
ous haemorrhage was reported in 13
eyes that received a mean (SD) of 3.8
(2.7) injections. Significantly fewer
injections 2.5 (1.6) were given to 16
eyes that developed rubeotic glaucoma
compared to the rest of the cohort
(p < 0.001). Rubeotic glaucoma devel-
oped more often in ranibizumab-
treated eyes (12 eyes vs 4 aflibercept-
treated eyes; p = 0.01); however, these
eyes received fewer injections 1.8 injec-
tions vs. 4.25 injections respectively.
Table 2. 12-month outcomes in all eyes and stratified by anti-VEGF agent received. Significant p-
values comparing ranibizumab and aflibercept are highlighted in bold.
Overall Ranibizumab Aflibercept p-value
No of Eyes 296 125 171
Baseline VA, mean (SD) 40.1 (25.8) 36.9 (26) 42.5 (25.5) 0.07
Final VA, mean (SD) 51.9 (28.5) 46.9 (29.4) 55.5 (27.3) 0.01
Crude VA change, mean (95%
CI)
11.8 (9, 14.5) 9.9 (5.8, 14.1) 13.1 (9.4, 16.8) 0.26
Adjusted VA change, mean (95%
CI)†
9.8 (5.5, 14.1) 16.6 (12.9,
20.4)
0.001
Gained ≥ 15 letters (%) 46% 40% 50% 0.10
Lost ≥ 15 letters (%) 10% 10% 11% 0.95
VA ≥ 70%Baseline / %Final 13% / 37% 13% / 30% 13% / 42% 1.00/
0.05
VA ≤ 35%Baseline / %Final 41% / 28% 45% / 34% 38% / 24% 0.29/
0.09
CST Baseline, mean (SD) 615 (236) 614 (240) 616 (234) 0.95
CST Final, mean (SD) 336 (169) 369 (179) 314 (159) 0.01














Completers, n (%) 236 (80%) 99 (79%) 137 (80%) 0.70
Switchers, n (%) 35 (12%) 26 (21%) 9 (5%) <0.001
Lost to follow-up, n (%) 60 (20%) 26 (21%) 34 (20%)
Injections, median (Q1, Q3)* 7 (5, 9) 6 (4, 9) 8 (5, 9) 0.62
Visits, median (Q1, Q3)* 10 (8, 13) 10 (7, 13) 10 (8, 13) 0.84
n = number, VA = visual acuity, SD = standard deviation, CI = confidence interval, CST = cen-
tral subfield thickness, Q1 = first quartile, Q3 = third quartile.
All eyes – includes completers, switchers and non-completers. ‘Completers’ – eyes with 12 months
of observation from the start of treatment, ‘switchers’ – eyes receiving ≥2 injections of the other
treatment drug prior to completion of 12 months from the start of treatment. Observations were
included in the analysis only up to the first occurrence of switching agents. ‘Non-Completers’
– eyes not completing 12 months of observations from the start of treatment.
* Last observation carried forward for switchers and non-completers.
† Calculated from longitudinal models adjusting for age and baseline VA (fixed effects), and
practice and intra-patient correlation for bilateral cases (random effects).
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Injection numbers overall, irrespective
of the agent, were strongly associated
with rubeotic glaucoma occurrence
(p < 0.001) suggesting the injection
number rather than the drug was asso-
ciated with rubeotic glaucoma. There
was one retinal detachment with VA at
12 months of light perception but no
reported cases of endophthalmitis or
traumatic cataract following 1915
injections.
Discussion
We report significant improvements in
VA and reductions in macular thickness
in eyes receiving aflibercept or ranibizu-
mab treatment for CRVO in routine
clinical practice. Both groups were well-
matched for gender, age, visual acuity
and CST at baseline. Both groups had
similar numbers of visits and injections
during the 12-month period. Our com-
parative analysis found that eyes receiv-
ing aflibercept had greater visual gains
and reductions in CST.
Significant differences in the molec-
ular structure and mode of action of
the drugs we studied may be the reason
for the better outcomes we found with
aflibercept for CRVO. While ranibizu-
mab is a humanized monoclonal anti-
body, aflibercept acts as a decoy-
receptor for VEGF and may offer
superior VEGF suppression due to
higher binding affinity against VEGF
(Papadopoulos et al. 2012) as well as
longer intravitreal half-life (Stewart &
Rosenfeld 2008). This may be particu-
larly important in eyes with CRVO,
which have very high vitreous levels of
VEGF (Aiello et al. 1994).
While treatment is mandated in
RCTs, treatment patterns greatly differ
in routine clinical practice due to var-
ious factors, including patient compli-
ance, cost and individual re-treatment
preferences. As a consequence, the
number of injections is often lower
than in RCTs as observed in the
current analysis and other database
studies (Lotery & Regnier 2015). Many
analyses of outcomes from routine
clinical practice have reported 4–5
injections for CRVO in the first year,
in contrast to RCTs which gave on
average 8.8–9.6 aflibercept injections
(Campochiaro et al. 2011) or 8.4
ranibizumab injections (Brown et al.
2013; Korobelnik et al. 2014) within
the first 12 months. Centres participat-
ing in the current analysis gave more
injections than have previously been
reported from routine clinical practice
(a median of 7 for both aflibercept and
ranibizumab), which is only slightly
fewer than in RCTs.
The combination of stronger and
potentially longer VEGF suppression
of aflibercept may be one of the main
drivers for better clinical outcomes
since the more prolonged suppression
may compensate for the somewhat
lower number of injections. Cystoid
macula oedema secondary to CRVO
may be a particularly attractive indica-
tion for new longer acting anti-VEGF
agents.
Patient population
The patient population in this analysis
from routine clinical practice was older
(mean 72 years) than patients included
in RCTs using aflibercept or ranibizu-
mab (range 61.5–69.7 years) (Cam-
pochiaro et al. 2011; Brown et al.
2013; Korobelnik et al. 2014; Larsen
et al. 2018). Patient eyes in the current
analysis had worse average baseline
VA scores (40.1 letters) than those
included in RCTs (range 47.4–53 let-
ters), with less thickened mean baseline
CST of 615 µm (range in RCTs 665–
693 µm) (Campochiaro et al. 2011;
Brown et al. 2013; Korobelnik et al.
2014; Larsen et al. 2018).
Visual outcomes and macular thickness
Visual outcomes for aflibercept and
ranibizumab, both adjusted (16.6 and
9.8) and unadjusted (13.1 and 9.9),
from this analysis were slightly inferior
to those observed in RCTs (13.9 to 18.9
letters; Campochiaro et al. 2011;
Brown et al. 2013; Korobelnik et al.
2014; Scott et al. 2017). Lower gains in
vision observed in this study were likely
due to differences in baseline charac-
teristics and lack of mandated treat-
ment every 4 weeks in the first
6 months. Also, the time from the
occurrence of the CRVO to treatment
Fig. 1. Graphical representation of vision and CST by drug. Predictions from longitudinal
generalized additive models of adjusted visual acuity (A, B) and CST (C, D). Red dotted lines in




initiation was not limited as in RCTs.
Fundus fluorescein angiography, per-
formed in around 60% of eyes, was
evenly distributed between both treat-
ment groups. A total of 7% and 25%
of eyes showed signs of macular
ischaemia and peripheral ischaemia
respectively. It seems unlikely that eyes
with macular ischaemia contributed
significantly to the observed reduced
VA gains of the total cohort, since
previous reports in ranibizumab-
treated eyes found that macular ischae-
mia did not influence VA outcomes
(Larsen et al. 2016; Tadayoni et al.
2017).
Aflibercept-treated eyes had more
significant reductions in CST than
ranibizumab-treated eyes. The Cox-
proportional hazards model predicted
that aflibercept was significantly faster
in achieving CMO inactivity than
ranibizumab (p = 0.02).
Switching treatments and loss of follow-up
Switching occurred in around 12% of
eyes, mainly from ranibizumab (21%)
rather than from aflibercept (5%). The
reason for switching was not recorded.
We hypothesize that it might have
included a perceived lack of response
by the treating physician. Loss of
follow-up was observed in 20% of eyes,
which is comparable to other observa-
tional studies. Ranibizumab was
approved for the treatment of CME
secondary to CRVO much earlier than
aflibercept. This might have influenced
the decision to switch too.
Adverse events
The rate and nature of adverse events,
such as macular atrophy, pigment
clumping or epiretinal membrane, in
our study population was relatively low
and about the same as in other diseases
treated with intravitreal anti-VEGF
such as diabetic retinopathy or age-
related macular degeneration.
An important detail is the number of
lasers and the fact that, despite anti-
VEGF treatment, rubeotic glaucoma
developed in 16 eyes – those eyes had
significantly fewer injections than the
rest of the cohort (mean 2.5 [1.6]). It
has now been established that the
requirement for panretinal laser pho-
tocoagulation in proliferative diabetic
retinopathy can be reduced by anti-
VEGF therapy (Writing Committee for
the Diabetic Retinopathy Clinical
Research et al. 2015; Sivaprasad et al.
2017). With the relatively higher VEGF
levels in patients with CRVO, one
might expect a similar benefit from
anti-VEGF therapy (Aiello et al. 1994).
However, the evidence base is not as
clear for the risk of neovascularization
in eyes with CRVO receiving anti-
VEGF therapy, especially when treat-
ment is stopped. Data from routine
clinical practice may provide useful
insights to the development and man-
agement of rubeosis in eyes receiving
VEGF inhibitors for CRVO.
Strengths and weaknesses
The current analysis has limitations
that are inherent to studies using data
from routine clinical practice. In con-
trast to RCTs, treatment decisions are
based on the physician’s observation in
consultation with the patient. The
choice of when to treat and to schedule
the next appointment also relies on the
patient’s availability to integrate fre-
quent appointments into a busy work
scheduled. Normally, no reading centre
recommendations or protocols are fol-
lowed as is the case in RCTs. There was
no randomization to treatment groups,
which, while not significant, resulted in
some differences in baseline character-
istics. We accounted for this partially
by adjusting for baseline factors that
might impact the outcome, such as age,
VA and CST.
The strengths of the current study
are the large sample size and an ade-
quate representation of how anti-
VEGF drugs are used in routine clin-
ical practice in a number of centres that
treat CRVO. The present study, which
had fortuitously well-matched baseline
characteristics, is unlikely to overesti-
mate either of the drugs’ effectiveness
(Concato et al. 2000).
Observational studies may suffer
from poor data quality. For example,
baseline and 12-month visual acuity
values could only be identified in
around half of the 30 000 otherwise
eligible eyes with neovascular age-
related macular degeneration in a
recent analysis from the IRIS database
Fig. 2. Kaplan–Meier curve for first grading of inactivity, time to switching and dropout by drug.
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(Kiss et al. 2020). By contrast, the
FRB! database only accepts ‘finalized’
data which is 100% complete and
within prespecified ranges, the finaliza-
tion rate is consistently above 95%.
Conclusions
This study found that both aflibercept
and ranibizumab improved VA and
reduced macular thickness over
12 months in eyes with CRVO. Afliber-
cept led to significantly greater
improvements, both in VA and CST.
Longer-term observational studies are
warranted to verify whether the initial
benefit of aflibercept and ranibizumab
is maintained.
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